Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 P288 | DOI: 10.1530/endoabs.99.P288

1Medical University of Sofia, Epidemiology and Hygiene, Sofia, Bulgaria; 2Medical University of Sofia, Internal Medicine, Sofia, Bulgaria


Background: Asprosin, a novel glucogenic adipokine, is encoded by two exons (exon 65 and exon66) of the gene Fibrillin 1 (FBN1) and mainly synthesized and released by white adipose tissue during fasting. Asprosin plays a complex role in the central nervous system (CNS), peripheral tissues, and organs. It is involved in appetite, glucose metabolism, insulin resistance (IR) and cell apoptosis.

Objective: The aim of the current study was to determine the levels of asprosin in subjects from the entire spectrum of the carbohydrate metabolism.

Methods: A total of 153 causcasian subjects participated in this study: group 1, healthy volunteers; group 2, obese subjects without glycemic disturbances; group 3- subjects with prediabetes and group 4, patients with newly identified type 2 diabetes

Results: Subject with body mass index ≥30 kg/m2 and dysglycemia (prediabetes and diabetes) showed significantly high levels of asprosin (1.40 ng/ml [IQR=0.98-1.94]; 1.27 ng/ml [IQR=0.86-2.12]; 1.09 ng/ml [IQR=0.89-1.58]) compared to the control group (0.71 ng/ml [IQR=0.54-0.92]; P<0.001). Correlation analysis showed that serum asprosin also had significant positive associations with some anthropometric parameters, liver enzymes, fasting and post load glucose and insulin, LDL and triglycerides. Furthermore, we estimated a markedly relationship between asprosin concentrations and intima media thickness of the common carotid artery as well as neuropathy disability and vibration sensitivity. The circulating asprosin levels for differentiating subjects with carbohydrate disturbances and those with obesity were determined by ROC analysis. The AUC for disturbances of the glucose metabolism was 0.672 (P<0.001; 95% CI =0.581-0.751) and for obesity AUC was 0.849 (P<0.001; 95% CI = 0.785-0.919).

Conclusion: Circulatin asprosin could be used as a predictive factor for early carbohydrate disorders and might be a potential new therapeutic target for the treatment of dysglycemia and obesity. Further prospective studies are needed to confirm this observation.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.